Dianthus Therapeutics | MGTA - Selling And Administration Expenses


Dianthus Therapeutics reported $13.56M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 424K 23K Jun/2026
Avita Medical AUD 19.54M 516K Jun/2026
Celltrion KRW 12.72B 3.4B Jun/2026
Cspc Pharmaceutical CNY 1.87B 95.62M Dec/2025
Deva Holding AS TRY 462.26M 48.18M Sep/2023
Dianthus Therapeutics USD 13.56M 1.09M Jun/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
IQVIA Holdings USD 569M 5M Sep/2026
Kangmei Pharma CNY 253.72M 16.66M Jun/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Moderna USD 282M 66M Sep/2026
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Organigram Holdings CAD 26.51M 4.5M Jun/2026
Organon & Co USD 407M 27M Sep/2026
Ovoca Bio EUR 617K 15K Dec/2025
Pharma Mar EUR 15.53M 1.59M Sep/2026
Qiagen NV USD 142.33M 60K Jun/2026
Revvity USD 275.33M 3.25M Sep/2026
Sartorius EUR 216.6M 4.7M Sep/2026
Sino Biopharmaceutical CNY 7.54B 2.23B Jun/2025
Tectonic Therapeutic USD 6.17M 260K Jun/2026
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 950.8M 183.7M Sep/2026
Xeris Pharmaceuticals USD 61.04M 7.89M Jun/2026
Zealand Pharma A/S 104M 12.19M Mar/2026
Zz Pientze Pharmaceu CNY 267.85M 44.71M Sep/2026